



PRESS RELEASE

November 8, 1999

Gambro acquires four dialysis clinics in the Midwest

Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that its wholly owned US subsidiary, GAMBRO Healthcare, Inc., acquired four dialysis clinics in the Midwest that will provide dialysis services to an additional 625 patients.

GAMBRO Healthcare, Inc. is a wholly owned subsidiary of Gambro AB, a world-leading medical technology and healthcare company. GAMBRO Healthcare is a fully integrated service provider in renal replacement therapy. Its activities include risk contracting, disease management, physician practice management, dialysis services, and clinical laboratory services.

GAMBRO Healthcare is the third largest provider of kidney dialysis services in the US. The Company now owns, operates, manages or provides consulting services to 484 dialysis centers in the United States. Through these dialysis centers Gambro now serves about 36,500 patients in centers across 33 states and the District of Columbia.

Gambro will continue its expansion of its clinics operations including further acquisitions of clinics. However, due to Y2k considerations no further acquisitions will be finalized before year end.

For further information please contact:

Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00,
+46-70-513 65 33

Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35,
+46-70-513 65 34

Tim Schoenberg, Vice President, US Investor Relations Manager, +1-949-425-2185

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 43,200 patients in some 580 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.